Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street

Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.58, $0.02 better than the analyst estimate of $1.56. Revenue for the quarter came in at $18.1 billion versus the consensus estimate of $18.28 billion.

GUIDANCE:

Johnson & Johnson sees FY2017 EPS of $6.93-$7.08, versus the consensus of $7.11. Johnson & Johnson sees FY2017 revenue of $74.1-74.8 billion, versus the consensus of $75.1 billion.

"We are pleased to report that we accelerated our adjusted growth for 2016 over the prior year, and delivered a strong total shareholder return of greater than 15 percent. The strong adjusted sales and EPS growth was driven by the impressive performance of our Pharmaceutical business and continued momentum in our Medical Device business and share gains while improving profitability in our Consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "Looking forward to 2017, we expect to continue driving sustainable, long-term growth through the new products, science and innovation that our talented colleagues and partners of Johnson & Johnson are advancing to positively impact human health."

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits